Midatech Pharma PLC Announces Results for the Year Ended 31 December 2020
ACCESSWIRE
Preliminary Results for the Year Ended 31 December 2020
ABINGDON, OXFORDSHIRE / ACCESSWIRE / April 30, 2021 / Midatech Pharma PLC (AIM:MTPH.L); (NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces its audited preliminary results for the year ended 31 December 2020.
Following the announcement of a Strategic Review in March 2020 and the termination of further in-house development of MTD201, the Company has broadened its R&D pipeline through technology collaborations with third party pharmaceutical companies, the initiation of new internal programmes and adding new indications to MTX110.
Midatech Pharma PLC Announces Results for the Year Ended 31 December 2020
Preliminary Results for the Year Ended 31 December 2020
ABINGDON, OXFORDSHIRE / ACCESSWIRE / April 30, 2021 / Midatech Pharma PLC (AIM:MTPH.L); (NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces its audited preliminary results for the year ended 31 December 2020.
Following the announcement of a Strategic Review in March 2020 and the termination of further in-house development of MTD201, the Company has broadened its R&D pipeline through technology collaborations with third party pharmaceutical companies, the initiation of new internal programmes and adding new indications to MTX110.
The Company s realigned strategy is to advance its development programmes to proof of concept stage before seeking licensee partners to fund further development, manufacturing scale-up and commercialisation.
MeaTech Reports 2020 Financial Results
USA - English
Highlights
· Commenced trading on TASE in January 2020 and Nasdaq in March 2021: first publicly traded cultured meat company, developing sustainable and ethical food technologies.
· Finalized acquisition of Peace of Meat BV ( POM ), a pioneering Belgian developer of cultured avian meat technologies, in February 2021.
· In November 2020, successfully bio-printed an edible cultured beef fat structure grown and developed from stem cells.
· 2020 year-end cash position was $13.5 million ($8.5 million pro-forma to POM acquisition) with further $28 million raised as part of the Nasdaq listing, bringing current cash position to $33.5 million.
News provided by
Share this article
Share this article
MeaTech 3D Announces Initiation of Food Technology Development Activities in Europe prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Published: Apr 19, 2021
Collaboration with NYS Department of Health’s Wadsworth Center continues for extended six-month term until September 30, 2021
Project utilizes OpGen’s Acuitas® AMR Gene Panel and Acuitas Lighthouse® Software within digital health and precision medicine platform at multiple healthcare institutions
GAITHERSBURG, Md., April 19, 2021 (GLOBE NEWSWIRE) OpGen, Inc.
(Nasdaq: OPGN) announced today that its strategic collaboration with the New York State Department of Health (“DOH”) to develop a state-of-the-art solution to detect, track, and manage antimicrobial-resistant infections at healthcare institutions statewide is being extended beyond the second-year expansion phase by another six months through September 30, 2021.
Having successfully achieved all of the milestones of the first and second year phases for the development of an infectious disease digital health and precision medicine platform that connects healthcare institutions